CalliSpheres载药微球-支气管动脉化疗栓塞联合免疫治疗晚期非小细胞肺癌患者的效果观察

doi:10.3969/j.issn.1006-6233.2025.05.030

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 观察CalliSpheres载药微球-支气管动脉化疗栓塞(DEB-BACE)联合免疫治疗晚期非小细胞肺癌(NSCLC)患者的疗效。方法: 回顾性分析2020年1月至2023年4月本院收治的142例晚期NSCLC患者资料,按照治疗方法的不同分为对照组(予以全身化疗联合免疫治疗)和观察组(予以CalliSpheres DEB-BACE联合免疫治疗),应用倾向性评分匹配法(卡钳值设置为0.01,1∶1匹配),最终两组各纳入71例基线资料可比患者。比较两组患者实体瘤疗效、治疗前后血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA-125)、细胞角质素片段抗原21-1(CYFRA21-1)]水平、T淋巴细胞亚群(CD3⁺、CD4⁺、CD4⁺/CD8⁺)及药物毒副反应、随访1年疾病进展情况(无进展生存期、总生存期)。结果: 观察组患者ORR、DCR分别为45.07%、80.28%,均高于对照组的23.35%、64.79%,差异均有统计学意义(P<0.05);治疗前,两组CEA、CA125、CYFRA21-1水平比较差异无统计学意义(P>0.05),治疗后,两组CEA、CA125、CYFRA21-1水平均下降(P<0.05),且观察组治疗前后差值高于对照组(P<0.05);治疗前,两组CD4⁺、CD3⁺、CD4⁺/CD8⁺水平比较差异无统计学意义(P>0.05),治疗后,观察组CD4⁺、CD3⁺、CD4⁺/CD8⁺水平均下降(P<0.05),观察组治疗前后差值低于对照组(P>0.05);观察组骨髓抑制发生率低于对照组(P<0.05);随访1年,观察组无进展生存期为(10.12±0.31)月,总生存期为(11.32±0.16)月,对照组无进展生存期为(8.56±0.38)月,总生存期为(10.42±0.27)月,观察组无进展生存、总生存情况均优于对照组(log rank χ²=6.416,P<0.05,log rank χ²=4.120,P=0.042)。结论: CalliSpheres用于DEB-BACE联合免疫治疗对晚期NSCLC安全有效。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	占明
	张弭
	张浩宇
	宋新宇

关键词 ：非小细胞肺癌, 载药微球, 支气管动脉化疗栓塞, 实体瘤疗效, 不良反应

Abstract：Objective: To observe the efficacy of CalliSpheres drug-eluting bead bronchial artery chemoembolization (DEB-BACE) combined with immunotherapy in advanced non-small cell lung cancer (NSCLC) patients. Methods: A retrospective analysis was performed on 142 advanced NSCLC patients admitted to our hospital from January 2020 to April 2023. Patients were divided into a control group (systemic chemotherapy combined with immunotherapy) and an observation group (CalliSpheres DEB-BACE combined with immunotherapy). Propensity score matching (caliper value set to 0.01, 1∶1 matching) was used, and 71 patients with comparable baseline data were finally included in each group. The efficacy on solid tumors, serum tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA-125), cytokeratin fragment antigen 21-1 (CYFRA21-1)] before and after treatment, T lymphocyte subsets (CD3⁺, CD4⁺, CD4⁺/CD8⁺), drug-related adverse reactions, and 1-year follow-up outcomes (progression-free survival, overall survival) were compared between the two groups. Results: The objective response rate (ORR) and disease control rate (DCR) in the observation group were 45.07% and 80.28%, respectively, significantly higher than 23.35% and 64.79% in the control group (P<0.05). Before treatment, there were no significant differences in CEA, CA125, and CYFRA21-1 levels between the two groups (P>0.05). After treatment, these markers decreased in both groups (P<0.05), with greater reductions observed in the observation group (P<0.05). Before treatment, CD4⁺, CD3⁺, and CD4⁺/CD8⁺ levels showed no significant differences (P>0.05). After treatment, CD4⁺, CD3⁺, and CD4⁺/CD8⁺ levels decreased in the observation group (P<0.05), with smaller changes compared to the control group (P>0.05). The incidence of bone marrow suppression was lower in the observation group (P<0.05). At 1-year follow-up, the observation group had a progression-free survival (PFS) of (10.12±0.31) months and an overall survival (OS) of (11.32±0.16) months, significantly better than the control group's PFS of (8.56±0.38) months and OS of (10.42±0.27) months (log rank χ²=6.416, P<0.05; log rank χ²=4.120, P=0.042). Conclusion: CalliSpheres DEB-BACE combined with immunotherapy is safe and effective for advanced NSCLC patients.

Key words： Non-small cell lung cancer Drug-eluting beads Transcatheter arterial chemoembolization Solid tumor efficacy Adverse reactions

基金资助:湖北省科技厅重点研发项目,(编号:2022BCE031)

通讯作者: 宋新宇

引用本文:

占明, 张弭, 张浩宇, 宋新宇. CalliSpheres载药微球-支气管动脉化疗栓塞联合免疫治疗晚期非小细胞肺癌患者的效果观察[J]. 河北医学, 2025, 31(5): 871-875.
ZHAN Ming, ZHANG Mi, ZHANG Haoyu, et al. Clinical Observation of CalliSpheres Drug-Eluting Bead Bronchial Artery Chemoembolization (DEB-BACE) Combined with Immunotherapy in Advanced Non-Small Cell Lung Cancer. HeBei Med, 2025, 31(5): 871-875.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2025.05.030 或 http://www.hbyxzzs.cn/CN/Y2025/V31/I5/871

[1] 中国抗癌协会整合肿瘤学分会,中国抗癌协会肿瘤标志专业委员会.非小细胞肺癌放疗联合免疫治疗中国专家共识(2024版)[J].中国癌症防治杂志,2024,16(5):505-515.
[2] Hutchings HE,Grady SC,Zhang Q,et al.Regional trends in diagnosis of advanced lung cancer in Michigan over 33 years[J].Thorac Dis,2024,16(5):2936-2947.
[3] Guan S,Ren K,Zhang X,et al.Concurrent chemoradiotherapy versus radiotherapy alone after induction chemoimmunotherapy for stage III NSCLC patients who did not undergo surgery:a single institution retrospective study[J].Radiat Oncol,2023,18(1):122.
[4] 中国抗癌协会肿瘤介入学专业委员会,刘玉金,伍筱梅,等.支气管动脉灌注术和支气管动脉化疗栓塞术治疗肺癌的中国专家共识(2023版)[J].介入放射学杂志,2024,33(3):219-229.
[5] Wang Q,Zhu L,Sheng Q.Clinical research progress of callisperes^® of drug-loaded microsphere arterial chemoembolisation in the treatment of solid tumors[J].Discov Oncol,2024,15(1):161.
[6] Bray F,Laversanne M,Sung H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer Clin,2024,74(3):229-263.
[7] Ma K,Guo Q,Li X.Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer:a real-world observation study[J].BMC Pulm Med,2023,23(1):175.
[8] 杜佳,李娟,李钱,等.新辅助放化疗联合动脉栓塞灌注治疗局部晚期直肠癌1例[J].国际肿瘤学杂志,2022,49(6):383-384.
[9] Jin B,Gu Y,Xi S,et al.Efficacy of CalliSpheres^® drug-loaded microspheres combined with doxorubicin in hepatocellular carcinoma[J].Scand Gastroenterol,2024,59(9):1087-1092.
[10] 程瑞文,郝若冰,李平,等.CalliSpheres药物洗脱微球和空白微球经动脉化疗栓塞术治疗中晚期非小细胞肺癌的比较[J].实用医学杂志,2024,40(1):32-37.